why Evofem Biosciences Inc. [EVFM] is a Good Choice for Investors After New Price Target of $16.25


Evofem Biosciences Inc. [NASDAQ: EVFM] surged by $0.0 during the normal trading session on Monday and reaching a high of $0.94 during the day while it closed the day at $0.86. The company report on July 25, 2022 that Evofem Biosciences Unveils New Educational Birth Control Chart to Assist Providers in Patient Contraceptive Counseling.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced it has developed a new educational birth control chart that provides high-level information about the different options available to women in the United States.

“Contraceptive counseling is one of the most important aspects of a healthcare provider’s job. It empowers women who do not wish to become pregnant to choose a method of birth control that aligns with their needs,” said Dr. Bassem Maximos, Head of Maximos Ob/Gyn in League City, Texas.  “Choosing the right birth control method should be an informed one and this chart recognizes the latest innovations in contraception.”.

Evofem Biosciences Inc. stock has also loss -1.80% of its value over the past 7 days. However, EVFM stock has declined by -70.91% in the 3 months of the year. Over the past six months meanwhile, it has lost -86.34% and lost -84.69% year-on date.

The market cap for EVFM stock reached $48.12 million, with 163.14 million shares outstanding and 155.32 million shares in the current float. Compared to the average trading volume of 32.32M shares, EVFM reached a trading volume of 13859214 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Evofem Biosciences Inc. [EVFM]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EVFM shares is $16.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EVFM stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Morgan Stanley have made an estimate for Evofem Biosciences Inc. shares, keeping their opinion on the stock as Underweight, with their previous recommendation back on October 14, 2021. While these analysts kept the previous recommendation, Stifel raised their target price to Buy. The new note on the price target was released on October 02, 2020, representing the official price target for Evofem Biosciences Inc. stock. Previously, the target price had yet another raise to $3, while Morgan Stanley analysts kept a Equal-Weight rating on EVFM stock.

The Average True Range (ATR) for Evofem Biosciences Inc. is set at 0.19, with the Price to Sales ratio for EVFM stock in the period of the last 12 months amounting to 4.22.

EVFM stock trade performance evaluation

Evofem Biosciences Inc. [EVFM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.80. With this latest performance, EVFM shares gained by 171.16% in over the last four-week period, additionally sinking by -86.34% over the last 6 months – not to mention a drop of -93.54% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EVFM stock in for the last two-week period is set at 47.64, with the RSI for the last a single of trading hit 46.02, and the three-weeks RSI is set at 45.75 for Evofem Biosciences Inc. [EVFM]. The present Moving Average for the last 50 days of trading for this stock 0.7169, while it was recorded at 0.8716 for the last single week of trading, and 5.0417 for the last 200 days.

Evofem Biosciences Inc. [EVFM]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Evofem Biosciences Inc. [EVFM] shares currently have an operating margin of -2023.30 and a Gross Margin at +21.37. Evofem Biosciences Inc.’s Net Margin is presently recorded at -2488.99.

Evofem Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.10 and a Current Ratio set at 0.10.

Evofem Biosciences Inc. [EVFM]: Insider Ownership positions

There are presently around $1 million, or 4.20% of EVFM stock, in the hands of institutional investors. The top three institutional holders of EVFM stocks are: VANGUARD GROUP INC with ownership of 427,971, which is approximately -6.438% of the company’s market cap and around 0.70% of the total institutional ownership; BLACKROCK INC., holding 260,687 shares of the stock with an approximate value of $0.23 million in EVFM stocks shares; and MIRADOR CAPITAL PARTNERS LP, currently with $0.16 million in EVFM stock with ownership of nearly 3408.679% of the company’s market capitalization.

Positions in Evofem Biosciences Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 27 institutional holders increased their position in Evofem Biosciences Inc. [NASDAQ:EVFM] by around 272,806 shares. Additionally, 24 investors decreased positions by around 489,005 shares, while 21 investors held positions by with 588,186 shares. The mentioned changes placed institutional holdings at 1,349,997 shares, according to the latest SEC report filing. EVFM stock had 10 new institutional investments in for a total of 10,262 shares, while 9 institutional investors sold positions of 262,143 shares during the same period.